RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
NCT06987513 on ClinicalTrials.gov · last registry update 2026-07-31
Finished 30 July 2026, after enrolling 100 people. Primary outcome, as filed: Change from baseline in the average number of heavy drinking days per week. pemvidutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P2
- Drug
- pemvidutide
- Sponsor
- Altimmune, Inc.
- Sponsor type
- Industry
- Enrollment
- 100
- Started
- 2025-05-15
- Primary completion
- 2026-07-30 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from baseline in the average number of heavy drinking days per week
Conditions studied
Alcohol Use Disorder (AUD)
Every field above is taken directly from the registry record. See all detected changes across the class, or the pemvidutide page for this molecule’s full trial and approval history.